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Racw. The Benestent trial is a nmdomized study comparing ekctlle Palmaz-Sekatz stent implautatioo with baIlooa angioplasty in patients with stable augina and a de aovo coronary arkry lesion. Seven-month bllow-up data have shown a decreased rate of resteaasis and fewer cliaifal events in tke steut group. It is not establisked wketber this favorable clhdcal auteome is maIntaioed for longer periods or wketber cmunary steatiag defers restenosis and its subsqueut clioical manifestatbus.
Mefhodv. To ckuify this oncednty, we updated clinical ioformation on all but I of 516 patients enrolled in tke Beuestent trial (257 in balloon group, 259 ia stent group) at least 12 ma&s after the intervention. Major clinical events (primary cliuical end point) were tabulated aeeordiug to tbe intention to treat priuciple and included de&, tke oeearreace of a cehvaxular accident, mytnxrdial in&r&u, the need for bypass surgery or a liuiber percutaneous intervention in the previously treated lesion.
Results. After 1 year, uo significant dikreuces in mortality (1.2% vs. 0.8%), stroke (0.0% vs. 0.8%). myocardial infarction (5.0% vs. 4.2%) or eoroaary bypass graft surgery (6.9% vs. 5.1%) were found between tke stent aad ballooa aagioplasty groups, respectiveIy. However, tke requirement for a repeat angioplasty prwcedure was sigailicantly lower ia tbe steut group (10%) than tbe balloaa angbphsty group (2196, rehtive risk [RR] 0.49,95% coafMie.ace interval ICI] 031 ta 0.75, p = O.OOl), aud overall primary end points w less frequeatly reacked by stent group patients (23.2%) than those in the baMoon group (315%, RR 0.74, 95% CI 055 to O.%, p = 0.64). No diiereaces were fouad between groups with respect to fi~octkmal class aagina and prescribed medIItioa at tke time of follow-up.
ConeLLFiofis. Tkese clinical follow-up data show that UK benefit of elective aative conmary artery steating in patients with stable auginais-toatIeastlyearaflertbepbeedurraud resaltsiaasi@&aatlyrPdmdreqoirrareotfarrepeatintmeatia CJAm Cdl Gdid l!W6;27:2S-61) 
Methods
Stody patients. Patients with stable angina and a single new lesion of the native coronary circulation were included in the study. Angiographic criteria for enrollment included a target lesion 4.5 mm long, located in a vessel >3 mm in diameter and supplying normally functioning myocardium. Angiographic exclusion criteria included ostial and bifurcation lesions, evidence of intracoronary thrombus, previously grafted vessels and severe vessel tortuosity. Other clinical exclusion criteria were age ~30 or >75 years, contraindication to anticoagulant or antiplatelet therapy, ineligibility for coronaty bypass surgery and any surgical intervention planned for the following 6 months. After providing verbal or written informed consent, patients telephoned a central office and were randomly assigned to either stent implantation or balloon angioplasty. Randomization was stratified according to center with blocks of six treatment assignments to ensure an equal distribution of treatments in each center. Clinical and angiographic characteristics of the study patients are shown in Table 1 .
Angioptasty procedure. Balloon angioplasty and stent implantation were performed according to standard clinical practice (13) . The articulated Palmaz-Schatz strnt (Johnson & Johnson Interventional Systems) was used. Details of design and placement technique of the Palmaz-Schatz coronary stent have previously been described (13, 16) . All patients received aspirin (250 to 500 mg daily) and dipyridamole (75 mg three times a day) at least from the day before to 6 months after intervention. Patients undergoing coronary stent implanta:ion were treated with a continuous infusion of dextran (1,000 ml over 6 to 8 h) and a 10,000-U bolus of unfractionated heparin at the commencement of the procedure. A heparin bolus was repeated hourly in the event of a prolonged procedure. The femoral sheaths were removed 6 to 8 h after the intervention. Oral anticoagulant therapy (warfarin) was started after shedth removal, and patients were kept on continuous intravenous heparin therapy (to maintain activated partial thromboplastin time between 60 and 90 s) for at least 36 h, until the prothrombin time had reached the therapeutic range (intemational normalized ratio 2.5 to 3.5). Warfarin therapy was continued for 3 months. Patients who underwent conventional balloon angioplasty received a 10,000-U bolus of unfractionated heparin followed by an additional bolus hourly if necessary. In addition, both treatment groups received calcium antagonists until hospital discharge, with further medical treatment left to the clinician's judgment.
CR&al follow-up. According to the original protocol, patients were seen in the outpatient clinic 1,3 and 6 months after the procedure. An interview, physical examination and electrocardiography were performed. Exercise testing was performed immediately before the 6.month hollow-up coronary angiogram unless early restudy had been clinically indicated. One year after the procedure, clinical information was obtamed dire&y from the patient at the outpatient clinic, by telephone interview or from the referring physician. At this time, a questionnaire was completed and included the follow- (48) 60 (23) 16 (6) Age ( (46) 62 (24) 17 (7) 48 (19) 52 (20) 5 (2) 0 8 (3) 5 (2) x0 (35) 80 (31) 95 (37) 89 w 6 (2) 6 (2) 8 (3) 10 (4) y (4) 75 (29) 1w (. (I) 20 (8) 23 (9) 89 (35) 9 (3) 82 (32) 125 (48) 16 (6) 27 (10) 89 W)
72 (28) 159 (62) 26 ( Primary clinical end points. The following clinical end points were included and ranked according to the most severe on the following scale: death, cerebrovascular accident, myocardial infarction, bypass surgery or a second percutaneous intervention involving the site of the previously treated lesion. All events were reviewed by the critical events committee, which was unaware of the treatment allocation. When, more than one clinical end point occurred in a patient, the event Cl 0.31 tc 9.75, p = 0.001). In accordance with these clinic-l data, the minimal lumen diameter at angiographic follow-up was greater after stent implantation than after balloon angioplasty (1.82 2 0.64 vs. 1.73 ? 0.55 mm, p = 0.09, median dirference 0.17 mm), and the incidence of restenosis at 7 months, according to the >50% stenosis criterion, was 22% after stent '-nplantation compared to 324, after balloon angioplasty (p = 0.02).
One-year follow-up. One year after the initial intervention, clinical follow-up information was available in all but one patient from the stent group (99.8%).
The mean follow-up period was 12 months (range 03 to 34). All interviews were performed at least I year after the intervention unless the patient had died in the intervening period. AI1 events = nonhierarchic listing of events at 1 year (e.g.. if a patient required repeat angioplasty and later coronary artety bypass graft surgety [CABG], the total taunt at 1 year would reflect both events, not just the worst event that occurred); Cl = confidence interval; CVA = aerehmvascular accident; Ml = myocardial infarction; I'KA = percutaneous transluminal coronary angtoplas~ -= not applicable.
(33%), information was obtained directly by, interview, by telephone in 256 (50%) and from the referring physician in the remaining 87 (17%). After 1 year of follow-up, 176 patients (685%) assigned to balloon angioplasty and 199 (76.8%) assigned to stent implantation were free of clinical events (p < 0.04). The difference in long-term clinical outcome is displayed in the cumulative distribution curves for the primary clinical end points in both treatment groups in Figure 1 . When repeat Figure 1 . Cumulative frequency distribution cutve for the two study groups showing percent of patients with primary clinical end points at foliow-ttp. Signiticant differences in the incidence of major clinical events appearing in the first 6 months are maintained at l-year f?ilOW-up. intervetttion was removed as a primary clinical end point, there was no significant difference in l-year event-free survival (87% for stent group, 89% for balloon group). Ranking for primary events and the total count of events at 1 year of follow-up are presented in Table 2 . A primary clinical end point occurred in 81 (32%) of the 257 patients randomly assigned to balloon angioplasty and in 60 (23%) of the 259 randomly assigned (0 stent implantation (RR 0.74, 95% CI 0.55 to 0.98, p = 0.04). The most striking difference in clinical outcome between the balloon and stent groups was a significantly reduced requirement for a further percutaneous intenention to the target lesion in the latter group (21% vs. IO%, respectively, RR 0.49, 95% CI 0.31 to 0.75, p = 0.001). The distribution of angina class at the time of follow-up was similar in both groups, with 86% of patients in the balloon group and 82% in the stem group remaining angina-free (Table 3) . Antianginal medication taken at the time of follow-up was similar in both groups (calcium antagonists 46% vs. 37%, beta-adrenergic blocking agents 31% vs. 25%, nitrates 16% vs. 13% and aspirin 88% vs. 91%, for the balloon and stent group patients, respectively). However, as we have shown, those patients who underwent balloon angioplasty required a repeat interventional procedure more frequently to remain symptom-free.
One-year status of patients event&e at 7.month followup. Primary clinical end points occurring after the 7-month follow-up assessment were rare. Of the 388 patients free of a primary event al 7-month follow-up, only 12 (3%) had a primary clinical event in the subsequent follow-up period. B = halloon; S = stent; DS = diameter stenosis; FUP = follow-up; Pent = after procedure; Pt = patient: Time = from intetventi~,nal procedure IO primary clinical event.
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Clinical and angiographic characteristics of these 12 patients are shown in Table 4 . Of these patients, eight had undergone primary coronary stenting, and four a balloon angioplasty. The most frequent late clinical event was a rr+ascularization procedure involving the target lesion (five repeat angioplasty, three bypass grafting). Additionally, there were three myocardial infarctions and one death. This s,;rall number of patients presenting with late clinical events does :rot permit a meaningful comparison between groups. However, five of the eight late revascularization procedures were perfcumed between 7 and 11 months of follow-up, and four of taese. five patients ha, already developed angiographic restenosis at 7-month followup.
Discussion
The present review of the 516 patients enrolled in the Benestent trial, where patients with stable angina were randomized to stent implantation or balloon angioplasty for the treatment of new coronary lesions, demonstrates that the superior clinical outcome observed at 7-month follow-up in patients who received a stent is maintained to at least 1 year after the intervention with a low incidence of new clinical events.
Clmical outcome in balloon and stent groups. The superior clinical outcome of patients who underwent stent implantation is supported by the larger minimal lumen diameter documented at Fmonth follow-up with a subsequent reduction in clinically significant restenosis (13) . However, it has been suggested (15) that the stent, a permanent metallic implant incorporated into the vessel wall, could prolong the time course over which intimal hyperplasia occurs and therefore. delay the appearance of restenosis to beyond the traditionally accepted period of 6 months. The results of our study show that the benefits obtained from stent implantation in the first 7 months are maintained at least to beyond the first year of follow-up, with no further increase in late (~7 months) prima2 events in stem group patients compared with balloon group patients. There is thus no evidence to suggest a delay in the restenosis process. It has been argued (21-23) that clinical events occurring 1 year after coronary interventions may most likely be related to the natural progression of atherosclerotic disease rather than to a delayed restenotic response to angioplasty-mediated arterial injury. Long-term angiographic follow-up studies (23) have shown a very low incidence (3%) of late stenosis at exactly the same site of previously dilated coronary segments in patients with a second coronary angiogram because of a recurrence of symptoms (23) .
Our results are also supported by nonrandomixed angiographic late follow-up studies (24) (25) (26) . Clinical events in the 300 stent group patients included death in 0.71, myocardial infarction in 3.7%, bypass grafting in 8% and repeat angioplasty in 13%. Eighty percent of stent group patients were free of an adverse event (24) . In addition, follow-up data for the National Heart Lung and Blood Institute-funded New Approaches in Coronary Intervention registry are being collected. However, the lack of a comparison group of patients with similar lesions treated by conventional balloon angioplasty remains an important limitation of this type of regisby (25 Early (4 months) versus late (>7 months) clinical outcome. The occurrence of a first primary end point beyond 7 months after the procedure was very low in our study patients (2.3%), and although the small number of patients does not allow statistical comparison, it is of interest that most late events were revascularization procedures involving the target lesion (eight events) and that most revascularization procedures were performed close to the 'I-month follow-up time in patients who had already developed restenosis at the time of angiographic follow-up (five events), suggesting that these "early" late events were in fact a consequence of a restenosis developing in the initial 7 months of follow-up. We suggest that by 7 months the adverse processes related to stent implantation, namely thrombotic occlusion and iutimal hyperplasia, have become manifest, and late clinical events are more likely to be related to the natural progression of the underlying atherosclerotic disease than to the device used at the time of coronary angioplasty.
When we exclude further coronary angioplasty as a major complication, an event that can be argued is a more benign complication than death, stroke, myocardial infarction or bypass surgery. we observe no significant difference in l-year outcome in the two treatment groups. However, it should not be forgotten that the coronary angioplasty procedure retains a small risk of mortality and morbidity. Additionally, there is a significant psychosocial impact on the patient and his or her family with every hospital admission, albeit for a "benign" procedure.
The economic benefit of stenting will be investigated prospectively in the Benestent Ii study. It has been suggested that the cost of the stent, which, without doubt. impacts significantly on the cost of the stenting procedure, compared with balloon angioplasty. will diminish as competition for the stent market increases.
Clinical impkations and conclusions. The excellent longterm survival after'elective percutaneous interventions in our study is not surprising because most patients had single-vessel disease and good left ventricular function, features known to be associated with an excellent long-term prognosis. Coronary angioplasty has been demonstrated (29) to be more successful in relieving angina pecteris and improving exercise tolerance than medical treatment in patients with stable single-vessel coronary artery disease. However, the results of angioplasty are hampered by a high incidence of restenosis (30% to 40%) after an initially successful ball,mn dilrtion (30) . Elective coronary stenting has been shown to improve the clinical and angiographic results of coronary angioplasty (13, 14) . However, these benefits are partially negated by the cost related to the stent itself, bleeding complications and a prolonged hospital stay (31, 32) . We eagerly await the results of trials of new stent designs, deployment strate@s and adjuvant therapies in an attempt to reduce or abolish these nondesirable effects (33, 34) . 
